Balcarek, J.M. et al. “Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase.” The Journal of Biological Chemistry 263(27):13937-41 (1988). |
Barnard, D.F. et al. “An evaluation of the Coulter VCS differential counter.” Clin. lab. Haernat. 11(3):255-66 (1989). |
Cyrus, T. et al. “Disruption of the 12/15-lipoxygenase gene diminishes artherosclerosis in apo-E-deficient mice.” The Journal of Clinical Investigation 103(11):1597-1604 (1999). |
Dixon, R.A.F. et al. “Cloning of the cDNA for human 5-lipoxygenase.” Proc. Natl. Acad. Sci. USA 85(2):416-20 (1988). |
Dwyer, J.H. et al. “Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.” The New England Journal of Medicine 350(1):29-37 (2004). |
Foresi, A. et al. “Eosinophils, mast cells, and basophils in induced sputum from patients with seasonal allergic rhinitis and perennial asthma: relationship to methacholine responsiveness.” J. Allergy Clin. Immunol. 100(1):58-64 (1997). |
Funk, C.D. et al. “Characterization of the human 5-lipoxygenase gene.” Proc. Natl. Acad. Sci. USA 86(8):2587-91 (1989). |
George, J. et al. “12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice.” Circulation 104:1646-50 (2001). |
Hoshiko, S. et al. “Characterization of the human 5-lipoxygenase gene promoter.” Proc. Natl. Acad. Sci. USA 87(23):9073-7 (1990). |
In, K.H. et al. “Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.” J. Clin. Invest. 99(5):1130-7 (1997). |
Israel, E. et al. “The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.” Annals of Internal Medicine 119(11):1059-66 (1993). |
Jatakanon, A. et al. “Changes in sputum eosinophils predict loss of asthma control.” Am. J. Respir. Crit. Care Med. 161(1):64-72 (2000). |
Khachigian, L.M. et al. “Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells.” The Journal of Biological Chemistry 270(46):27679-86 (1995). |
Li, L. et al. “Positive regulation of human α1 (I) collagen promoter activity by transciption factor Sp1.” Gene 164(2):229-34 (1995). |
Lönnkvist, K. et al. “Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal.” J. Allergy Clin. Immunol. 107(5):812-7 (2001). |
Matsumoto, T. et al. “Molecular cloning and amino acid sequence of human 5-lipoxygenase.” Proc. Natl. Acad. Sci. USA 85(1):26-30 (1988). |
Matsumoto, T. et al. “Correction to Proc. Natl. Acad. Sci. USA 85(1):26-30 (1988).” Proc. Natl. Acad. Sci. USA 85(10):3406 (1988). |
Moffitt, J.E. et al. “Management of asthma in children.” American Family Physician 50(5):1039-50, 1053-5 (1994). |
O'Byrne, P.M. “Leukotrienes in the pathogenesis of asthma.” Chest 111(2 Suppl):27S-34S (1997). |
Persson, M.G. et al. “Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits.” Anesthesiology 82(4):969-74 (1995). |
Powell, W.S. et al. “Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis.” J. Allergy Clin. Immunol. 107(2):272-8 (2001). |
Samuelsson, B. “Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.” 220(4597):568-75 Science (1983). |
Samuelsson, B. et al. “Leukotrienes and lipoxins: structures, biosynthesis, and biological effects.” Science 237(4819):1171-6 (1987). |
Silverman, E. et al. “Pharmacogenetics of the 5-lipoxygenase pathway in asthma.” Clinical and Experimental Allergy 28 Suppl 5:164-70 (1998). |
Tang, J-L. et al. “Role of Sp1 in transcriptional activation of human nitric oxide synthase type III gene.” Biochemical and Biophysical Research Communications 213(2):673-80 (1995). |
Ulrik, C.S. “Eosinophils and pulmonary function: an epidemiologic study of adolescents and young adults.” Annals of Allergy, Asthma, & Immunology 80(6):487-93 (1998). |
Urasaki, T. et al. “Pivotal role of 5-lipoxygenase in the activation of human eosinophils: platelet-activating factor and interleukin-5 induce CD69 on eosinophils throught the 5-lipoxygenase pathway.” Journal of Leukocyte Biology 69(1):105-12 (2001). |
Wariishi, S. et al. “A SP1 binding site in the GC-rich region is essential for a core promoter activity of the human endothelial nitric oxide synthase gene.” Biochemical and Biophysical Research Communications 216(2):729-35 (1995). |